血尿癌症风险评分联合超声指导血尿患者膀胱镜使用
本研究基于英国40家医院1984例血尿患者(DETECT 1)开发队列及500例独立验证队列,评估血尿癌症风险评分(HCRS)联合肾膀胱超声(RBUS)指导膀胱镜使用的能力。验证队列HCRS的AUC为0.727(95%CI 0.648-0.800),灵敏度95%;联合RBUS后开发队列680例(34%)可避免膀胱镜但漏诊1例G1 Ta膀胱癌和1例尿路癌,验证队列117例(25%)可避免膀胱镜但漏诊1例G1 Ta膀胱癌,灵敏度97%。
要点
- HCRS联合RBUS在验证队列中识别癌症的灵敏度为97%,AUC为0.727。
- 开发队列680例(34%)可避免膀胱镜,代价为漏诊1例G1 Ta膀胱癌和1例尿路癌。
- 验证队列117例(25%)可避免膀胱镜,代价为漏诊1例G1 Ta膀胱癌。
核心结论
- HCRS联合RBUS在识别可从膀胱镜获益的血尿患者方面具有良好区分能力,可使部分患者队列免于有创检查。
研究设计与样本
- 开发队列为来自英国40家医院的1984例接受RBUS的血尿患者(DETECT 1;ClinicalTrials.gov:NCT02676180)。
- 独立验证队列为因怀疑膀胱癌转诊至二级医疗机构的500例连续患者。
主要发现
- 开发队列134例(7%)和验证队列36例(8%)患者诊断为尿路癌症。
- 验证队列中HCRS的AUC为0.727(95%CI 0.648-0.800),识别癌症的灵敏度为95%。
- 开发队列采用HCRS推导的 cutoff 4.500联合RBUS,680例(34%)可避免膀胱镜,代价为漏诊1例G1 Ta膀胱癌和1例尿路癌患者。
- 验证队列117例(25%)可避免膀胱镜,代价为漏诊1例G1 Ta膀胱癌患者,识别癌症的灵敏度为97%。
关键数值与推荐
- HCRS cut off 为4.500,联合RBUS用于开发队列的膀胱镜分流。
- 验证队列HCRS识别癌症的灵敏度为95%,联合RBUS后灵敏度为97%。
临床怎么用
- HCRS联合RBUS可用于血尿患者的分流,识别可从膀胱镜获益的患者,使部分患者安全免于膀胱镜并节省医疗成本。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hematuria is a cardinal symptom of urinary tract cancer and would require further investigations. OBJECTIVE: To determine the ability of renal bladder ultrasound (RBUS) with the Hematuria Cancer Risk Score (HCRS) to inform cystoscopy use in patients with hematuria. DESIGN, SETTING, AND PARTICIPANTS: The development cohort comprised 1984 patients with hematuria from 40 UK hospitals (DETECT 1; ClinicalTrials.gov: NCT02676180) who received RBUS. An independent validation cohort comprised 500 consecutive patients referred to secondary care for a suspicion of bladder cancer. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Sensitivity and true negative of the HCRS and RBUS were assessed. RESULTS AND LIMITATIONS: A total of 134 (7%) and 36 (8%) patients in the development and validation cohorts, respectively, had a diagnosis of urinary tract cancer. Validation of the HCRS achieves good discrimination with an area under the receiver operating characteristic curve of 0.727 (95% confidence interval 0.648-0.800) in the validation cohort with sensitivity of 95% for the identification of cancer. Utilizing the cutoff of 4.500 derived from the HCRS in combination with RBUS in the development cohort, 680 (34%) patients would have been spared cystoscopy at the cost of missing a G1 Ta bladder cancer and a urinary tract cancer patient, while 117 (25%) patients would have avoided cystoscopy at the cost of missing a single patient of G1 Ta bladder cancer with sensitivity for the identification of cancer of 97% in the validation cohort. CONCLUSIONS: The HCRS with RBUS offers good discriminatory ability in identifying patients who would benefit from cystoscopy, sparing selected patient cohorts from an invasive procedure. PATIENT SUMMARY: The hematuria cancer risk score with renal bladder ultrasound allows for the triage of patients with hematuria who would benefit from visual examination of the bladder (cystoscopy). This resulted in 25% of patients safely omitting cystoscopy, which is an invasive procedure, and would lead to health care cost savings.
引用
- Tan WS, Ahmad A, Zhou Y, et al. Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria. Eur Urol Oncol. 2024. PMID: 38811250. doi:10.1016/j.euo.2024.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。